Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]

[This corrects the article DOI: 10.1016/j.jtocrr.2022.100431.].

• Garassino, M. C.
• Gadgeel, S.
• Novello, S.
• Halmos, B.
• Felip, E.
• Speranza, G.
• Hui, R.
• Garon, E. B.
• Horinouchi, H.
• Sugawara, S.
• Rodriguez-Abreu, D.
• Reck, M.
• Cristescu, R.
• Aurora-Garg, D.
• Loboda, A.
• Lunceford, J.
• Kobie, J.
• Ayers, M.
• Piperdi, B.
• Pietanza, M. C.
• Paz-Ares, L.